Park Jang Hyun, Lee Heung Kyu
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
Vaccines (Basel). 2021 May 19;9(5):524. doi: 10.3390/vaccines9050524.
The novel coronavirus, SARS-CoV-2, which causes COVID-19, has resulted in a pandemic with millions of deaths. To eradicate SARS-CoV-2 and prevent further infections, many vaccine candidates have been developed. These vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. In contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. Although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens. However, a lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in only intramuscular vaccinations. In this review, we summarize the history of vaccines, current progress in COVID-19 vaccine technology, and the status of intranasal COVID-19 vaccines. Future research should determine the most effective route for vaccine delivery based on the platform and determine the mechanisms that underlie the efficacy of different delivery routes.
导致新冠肺炎的新型冠状病毒SARS-CoV-2已引发一场造成数百万人死亡的大流行。为了根除SARS-CoV-2并防止进一步感染,人们研发了许多候选疫苗。这些疫苗不仅包括传统的亚单位疫苗、减毒或灭活病毒疫苗,还包括核酸疫苗和病毒载体疫苗。与平台技术的多样性形成对比的是,疫苗的接种方式仅限于肌肉注射。尽管肌肉注射疫苗安全有效,但黏膜接种疫苗可以改善局部免疫反应,从而阻止病原体传播。然而,由于对黏膜免疫缺乏了解,再加上对新冠肺炎疫苗的迫切需求,目前只有肌肉注射这一种接种方式。在这篇综述中,我们总结了疫苗的发展历程、新冠肺炎疫苗技术的当前进展以及鼻内新冠肺炎疫苗的现状。未来的研究应根据平台确定最有效的疫苗接种途径,并确定不同接种途径有效性背后的机制。